{"id":"etanercept-enbrel","safety":{"commonSideEffects":[{"rate":"10–26","effect":"Injection site reactions"},{"rate":"5–10","effect":"Upper respiratory tract infections"},{"rate":"5–10","effect":"Headache"},{"rate":"1–3","effect":"Serious infections (including tuberculosis)"},{"rate":"rare","effect":"Demyelinating disorders"},{"rate":"rare","effect":"Congestive heart failure exacerbation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etanercept consists of the extracellular ligand-binding domain of the human TNF receptor II fused to the Fc portion of human IgG1. It acts as a soluble TNF receptor that competitively binds circulating TNF-α and TNF-β, preventing their interaction with cell-surface TNF receptors and thereby suppressing the inflammatory cascade. This TNF inhibition reduces immune cell activation and inflammatory cytokine production in autoimmune and inflammatory conditions.","oneSentence":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine driving immune-mediated diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:47.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Plaque psoriasis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT02840175","phase":"PHASE3","title":"Treatment Tapering in JIA With Inactive Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-18","conditions":"Juvenile Idiopathic Arthritis","enrollment":62},{"nctId":"NCT05891600","phase":"","title":"A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-06-06","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT03792841","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC","status":"TERMINATED","sponsor":"Amgen","startDate":"2019-02-05","conditions":"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer","enrollment":212},{"nctId":"NCT06392074","phase":"PHASE1","title":"A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2024-03-07","conditions":"Healthy Volunteers","enrollment":141},{"nctId":"NCT07184853","phase":"NA","title":"Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-25","conditions":"Graft vs Host Disease","enrollment":122},{"nctId":"NCT06596772","phase":"PHASE3","title":"A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"mAbxience Research S.L.","startDate":"2024-10-03","conditions":"Rheumatoid Arthritis (RA)","enrollment":458},{"nctId":"NCT00679042","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"CellTrans Inc.","startDate":"2007-09-05","conditions":"Type 1 Diabetes Mellitus","enrollment":21},{"nctId":"NCT04485325","phase":"PHASE4","title":"Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients","status":"COMPLETED","sponsor":"Dr. Frank Behrens","startDate":"2019-11-04","conditions":"Rheumatic Arthritis","enrollment":92},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT00730392","phase":"PHASE1, PHASE2","title":"Etanercept in New Onset Type 1 Diabetes","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2002-10","conditions":"Type 1 Diabetes","enrollment":18},{"nctId":"NCT04559412","phase":"PHASE1","title":"Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2021-03-15","conditions":"Rheumatoid Arthritis","enrollment":11},{"nctId":"NCT03100253","phase":"PHASE4","title":"Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-03-01","conditions":"Rheumatoid Arthritis","enrollment":208},{"nctId":"NCT05424393","phase":"","title":"Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-03-04","conditions":"Rheumatoid Arthritis","enrollment":500},{"nctId":"NCT03033095","phase":"NA","title":"Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2016-07","conditions":"Spondylitis, Ankylosing","enrollment":50},{"nctId":"NCT02821026","phase":"PHASE1, PHASE2","title":"Omental Islet Transplant","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2016-05","conditions":"Type 1 Diabetes","enrollment":4},{"nctId":"NCT00224874","phase":"PHASE2","title":"Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2005-09","conditions":"Graft vs Host Disease, Immune System Disorders","enrollment":180},{"nctId":"NCT00421174","phase":"PHASE3","title":"Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2007-08","conditions":"Pneumonia, Idiopathic Pneumonia Syndrome","enrollment":37},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT00837434","phase":"PHASE4","title":"Anti-TNF Agents for the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":63},{"nctId":"NCT02464033","phase":"PHASE2","title":"EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Johnny Ludvigsson","startDate":"2015-05","conditions":"Diabetes Mellitus, Type 1","enrollment":20},{"nctId":"NCT01394913","phase":"PHASE3","title":"Comparison of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis","status":"WITHDRAWN","sponsor":"EMS","startDate":"2013-08","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT03100734","phase":"","title":"Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-06-01","conditions":"Rheumatoid Arthritis, Axial Spondyloarthritis","enrollment":585},{"nctId":"NCT01764321","phase":"","title":"Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":1723},{"nctId":"NCT00346294","phase":"PHASE4","title":"An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-01","conditions":"Rheumatoid Arthritis","enrollment":115},{"nctId":"NCT03016260","phase":"","title":"RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"TcLand Expression S.A.","startDate":"2016-12","conditions":"RheumatoId Arthritis","enrollment":250},{"nctId":"NCT02364479","phase":"PHASE4","title":"Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-02-10","conditions":"Spondyloarthritis","enrollment":150},{"nctId":"NCT02960035","phase":"PHASE4","title":"A Study of the MASEI in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-04","conditions":"Spondyloarthropathy","enrollment":96},{"nctId":"NCT04077957","phase":"PHASE4","title":"Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2019-10-07","conditions":"Ankylosing Spondylitis, Spondyloarthritis","enrollment":100},{"nctId":"NCT00078806","phase":"PHASE3","title":"Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Amgen","startDate":"2001-06-04","conditions":"Juvenile Rheumatoid Arthritis","enrollment":19},{"nctId":"NCT01623752","phase":"","title":"Prospective Evaluation of the Radiographic Efficacy of Enbrel","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-02","conditions":"Rheumatoid Arthritis, Psoriasis Arthritis","enrollment":1821},{"nctId":"NCT00078819","phase":"PHASE3","title":"Etanercept (Enbrel®) in Psoriasis - Pediatrics","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-09-08","conditions":"Psoriasis","enrollment":211},{"nctId":"NCT01865552","phase":"PHASE1","title":"Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2013-05","conditions":"Healthy","enrollment":138},{"nctId":"NCT03827876","phase":"PHASE4","title":"Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2019-01-16","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT01877239","phase":"","title":"Study to Observe the Safety and Efficacy of Etanercept (Enbrel®) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-12-10","conditions":"Rheumatoid Arthritis","enrollment":111},{"nctId":"NCT03327454","phase":"","title":"Benepali® PEN Patient Satisfaction Survey","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-08-10","conditions":"Rheumatoid Arthritis, Spondyloarthropathies","enrollment":500},{"nctId":"NCT02638259","phase":"PHASE3","title":"Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sandoz","startDate":"2015-02-21","conditions":"Rheumatoid Arthritis","enrollment":376},{"nctId":"NCT03273088","phase":"PHASE1","title":"Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects","status":"COMPLETED","sponsor":"AryoGen Pharmed Co.","startDate":"2016-12-04","conditions":"Phase 1, Bioequivalence","enrollment":34},{"nctId":"NCT01875991","phase":"PHASE4","title":"Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-06-05","conditions":"Rheumatoid Arthritis, Plaque Psoriasis","enrollment":217},{"nctId":"NCT01901185","phase":"PHASE3","title":"Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-06-11","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis","enrollment":77},{"nctId":"NCT01927757","phase":"PHASE4","title":"Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab","status":"TERMINATED","sponsor":"Amgen","startDate":"2013-05-06","conditions":"Moderate to Severe Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT03403140","phase":"PHASE3","title":"Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )","status":"UNKNOWN","sponsor":"Gema Biotech S.A.","startDate":"2016-10-06","conditions":"Rheumatoid Arthritis","enrollment":141},{"nctId":"NCT01543204","phase":"PHASE4","title":"Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab","status":"TERMINATED","sponsor":"Amgen","startDate":"2012-02-01","conditions":"Psoriasis","enrollment":64},{"nctId":"NCT00201838","phase":"PHASE1, PHASE2","title":"Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2001-07","conditions":"Pancreatic Neoplasms, Adenocarcinoma","enrollment":38},{"nctId":"NCT03332719","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of Enerceptan Compared to Enbrel in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Gema Biotech S.A.","startDate":"2016-02","conditions":"Rheumatoid Arthritis","enrollment":168},{"nctId":"NCT00141921","phase":"PHASE3","title":"Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-08-11","conditions":"Pediatric Plaque Psoriasis","enrollment":182},{"nctId":"NCT00309907","phase":"PHASE2","title":"Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2006-04","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission","enrollment":39},{"nctId":"NCT01895309","phase":"PHASE3","title":"A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2013-06","conditions":"Rheumatoid Arthritis","enrollment":596},{"nctId":"NCT01294397","phase":"PHASE1","title":"Effects of Denosumab on the Pharmacokinetics of Etanercept","status":"TERMINATED","sponsor":"Amgen","startDate":"2011-03","conditions":"Postmenopausal, Osteopenia, Rheumatoid Arthritis","enrollment":19},{"nctId":"NCT01891864","phase":"PHASE3","title":"Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel","status":"COMPLETED","sponsor":"Sandoz","startDate":"2013-06","conditions":"Chronic Stable Plaque Psoriasis","enrollment":531},{"nctId":"NCT02346877","phase":"PHASE4","title":"Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adults With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Amgen","startDate":"2015-04","conditions":"Persistence to Enbrel","enrollment":19},{"nctId":"NCT00201682","phase":"PHASE1, PHASE2","title":"Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"John Byrd","startDate":"2002-10","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":36},{"nctId":"NCT02274792","phase":"PHASE4","title":"Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-01","conditions":"Plaque Psoriasis","enrollment":132},{"nctId":"NCT02999776","phase":"PHASE1","title":"Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis","status":"UNKNOWN","sponsor":"Pantec Biosolutions AG","startDate":"2016-11","conditions":"Psoriatic Plaque","enrollment":30},{"nctId":"NCT02322580","phase":"","title":"An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2015-01","conditions":"Psoriasis","enrollment":56},{"nctId":"NCT01894412","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hanwha Chemical","startDate":"2013-07","conditions":"Healthy","enrollment":48},{"nctId":"NCT02799498","phase":"PHASE1","title":"Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual Injection","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-10","conditions":"Healthy Men and Women","enrollment":36},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT01716637","phase":"PHASE1","title":"Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Life Extension Foundation Inc.","startDate":"2010-02","conditions":"Alzheimer's Disease","enrollment":12},{"nctId":"NCT02701205","phase":"PHASE3","title":"Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis","status":"UNKNOWN","sponsor":"Shanghai Celgen Bio-Pharmaceutical Co.,Ltd","startDate":"2015-01","conditions":"Plaque Psoriasis, Psoriasis","enrollment":216},{"nctId":"NCT02357069","phase":"PHASE3","title":"A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"UNKNOWN","sponsor":"LG Life Sciences","startDate":"2015-02","conditions":"Arthritis, Rheumatoid","enrollment":372},{"nctId":"NCT02588534","phase":"PHASE1","title":"Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Thigh to Compare an Auto-injector Device and a Manual Injection in Healthy Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08","conditions":"Healthy Men and Women","enrollment":36},{"nctId":"NCT00708708","phase":"","title":"Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-06","conditions":"Psoriasis","enrollment":926},{"nctId":"NCT02112097","phase":"PHASE1, PHASE2","title":"ASIS for Enbrel in Plaque Psoriasis","status":"UNKNOWN","sponsor":"ASIS Corporation","startDate":"2016-01","conditions":"Plaque Psoriasis.","enrollment":60},{"nctId":"NCT01490047","phase":"PHASE1","title":"Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas","status":"WITHDRAWN","sponsor":"Ludwig Institute for Cancer Research","startDate":"2013-01","conditions":"Solid Tumors, Lymphomas","enrollment":""},{"nctId":"NCT00724672","phase":"","title":"A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT01725620","phase":"PHASE1","title":"Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel®","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2012-11","conditions":"Healthy","enrollment":48},{"nctId":"NCT01276847","phase":"PHASE1","title":"A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03","conditions":"Psoriasis","enrollment":40},{"nctId":"NCT00488475","phase":"","title":"Observational Trial With Enbrel","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-09","conditions":"Rheumatoid Arthritis","enrollment":4945},{"nctId":"NCT00654368","phase":"PHASE4","title":"CAMEO: Canadian Methotrexate and Etanercept Outcome Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-06","conditions":"Rheumatoid Arthritis","enrollment":258},{"nctId":"NCT00791765","phase":"PHASE4","title":"Moderate to Severe Plaque Psoriasis With Scalp Involvement","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-10","conditions":"Psoriasis","enrollment":124},{"nctId":"NCT01044836","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics of HD203 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hanwha Chemical","startDate":"2010-01","conditions":"Healthy","enrollment":42},{"nctId":"NCT01270997","phase":"PHASE3","title":"Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients","status":"COMPLETED","sponsor":"Hanwha Chemical","startDate":"2010-12","conditions":"Rheumatoid Arthritis","enrollment":294},{"nctId":"NCT00127842","phase":"PHASE4","title":"REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-08","conditions":"Psoriatic Arthritis","enrollment":110},{"nctId":"NCT00293722","phase":"","title":"Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-01","conditions":"Arthritis, Psoriatic, Psoriasis, Skin Diseases, Papulosquamous","enrollment":1308},{"nctId":"NCT00293709","phase":"","title":"Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-01","conditions":"Arthritis, Psoriatic, Psoriasis, Skin Diseases, Papulosquamous","enrollment":129},{"nctId":"NCT00361634","phase":"PHASE1","title":"Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-09","conditions":"Rheumatoid Arthritis","enrollment":14},{"nctId":"NCT00115219","phase":"PHASE4","title":"Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-05","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT00111124","phase":"PHASE4","title":"Enbrel® in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Psoriasis","enrollment":""},{"nctId":"NCT00111449","phase":"PHASE3","title":"Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-06","conditions":"Psoriasis","enrollment":600},{"nctId":"NCT00078793","phase":"","title":"Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2000-06","conditions":"Juvenile Rheumatoid Arthritis","enrollment":600},{"nctId":"NCT00111436","phase":"PHASE3","title":"Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-04","conditions":"Psoriasis","enrollment":912},{"nctId":"NCT00141713","phase":"PHASE2","title":"The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2003-10","conditions":"Graft-Versus-Host Disease","enrollment":40},{"nctId":"NCT01188655","phase":"","title":"Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-05","conditions":"Spondylitis, Ankylosing","enrollment":89},{"nctId":"NCT00116727","phase":"","title":"Rheumatoid Arthritis DMARD Intervention and UtilizationStudy","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-10","conditions":"Rheumatoid Arthritis","enrollment":5103},{"nctId":"NCT01145950","phase":"PHASE1","title":"Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2010-06","conditions":"Healthy","enrollment":36},{"nctId":"NCT00797784","phase":"PHASE2","title":"The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus","status":"UNKNOWN","sponsor":"Florida Academic Dermatology Centers","startDate":"2008-10","conditions":"Discoid Lupus Erythematosus (DLE)","enrollment":20},{"nctId":"NCT00099554","phase":"PHASE4","title":"Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-05","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT00844142","phase":"PHASE2","title":"Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2005-11","conditions":"Moderate to Severe Active Axial Spondyloarthritis","enrollment":80},{"nctId":"NCT00094341","phase":"PHASE4","title":"Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-10","conditions":"Rheumatoid Arthritis","enrollment":215},{"nctId":"NCT00121056","phase":"","title":"REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-09","conditions":"Rheumatoid Arthritis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Etanercept (ENBREL®)","genericName":"Etanercept (ENBREL®)","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine driving immune-mediated diseases. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}